Title

Clinical Relevance of Cabohydrate Antigen 19-9 Level after Chemoradiotherapy in Rectal Cancer Patients with Normal Carcinoembryonic Antigen Level

Translated Titles

以CA 19-9值來評估,癌胚抗原(CEA)值正常的直腸癌病患在接受術前放射線化療(CRT)後的預後

DOI

10.6312/SCRSTW.2014.25(3).10322

Authors

黃志生(Chih-Sheng Huang);林春吉(Chun-Chi Lin);藍苑慈(Yuan-Tzu Lan);楊純豪(Shung-Haur Yang);王煥昇(Huann-Sheng Wang);姜正愷(Jeng-Kai Jiang);陳維熊(Wei-Shone Chen);林資琛(Tzu-Chen Lin);林楨國(Jen-Kou Lin);張世慶(Shin-Ching Chang)

Key Words

直腸癌 ; 手術前放化療 ; Rectal cancer ; Pre-opera Tive Chemoradiotherapy ; CA 19-9

PublicationName

中華民國大腸直腸外科醫學會雜誌

Volume or Term/Year and Month of Publication

25卷3期(2014 / 09 / 01)

Page #

106 - 114

Content Language

英文

Chinese Abstract

目的 癌胚抗原(CEA)是最廣泛使用的大腸直腸癌腫瘤指數。然而,對於CEA值正常的直腸癌病患,目前並沒有一個好的腫瘤標記來評估預後或者是追蹤病情。我們這個研究目的在探討直腸癌患者在接受術前放射線化療(CRT)後,其CA19-9值是否可以拿來作為病患的預後因子。方法 自2000年1月至2010年12月,共有474名直腸癌患者在台北榮總大腸直腸外科接受完整的術前CRT合併手術治療。部分患者因為各種因素被排除,其中包含第四期患者(n = 114),腫瘤位於直腸上段(n = 5),經肛門切除(n = 7),CEA > 5(n = 108),缺乏完整CA19-9數據(N = 105)。最後剩下135名患者進入研究。所有患者進行了完整的術前評估以及術後的追蹤,本實驗主要是要做病患分組間的生存分析以及其他臨床病理檢查結果的比較。結果 本次研究的結果顯示出,post-CRT 19-9以及ypN這兩個變項對於直腸癌病患的5年無疾病存活期(disease free survival)為獨立的預後因子。我們的研究另外發現post-CRT 19-9的上升也和腫瘤的肺部轉移有關連性。結論 對於post-CRT 19-9上升的直腸癌病患,我們應該後續追蹤的部分得更加注意有無復發之情形,特別是肺部的部分。

English Abstract

Purpose. This study aimed to investigate the role of carbohydrate antigen 19-9 (CA19-9) in rectal cancer patients with normal carcinoembryonic antigen (CEA). Patients and Methods. From Jan 2001 to Dec 2010, 135 Patients who underwent preoperative chemoradiotherapy (CRT) followed by radical surgical resection were retrospectively enrolled from a prospectively constructed database. Characteristics of patients according to pre-CRT andpost-CRT CA19-9 concentrations were analyzed. Results. Patients with high post-CRT CA19-9 (≥ 37.0 u/ml) level were likely to have higher lymph node metastasis rate and tumor recurrence rate than those with normal post-CRT CA19-9 (< 37.0 ng/ml) level. Univariate and multivariate analysis showed that post-CRT CA19-9 level (HR = 8.474, 95% CI = 1.006~71.403) and ypN stage (HR = 2.422, 95% CI = 1.098~5.346) were independent prognostic factors for disease free survival rate.We also found that patients with high levels of post-CRT CA19-9 had a higher risk of lung metastasis (50.0% vs. 14.4%, p = 0.013). Conclusions. Post-CRT CA19-9 level might be an independent prognostic factor for disease-free survival in rectal cancer patients with normal (< 5 ng/ml) pre-CRT CEA treated with preoperative CRT and radical surgery. An aggressive surveillance protocol for lung metastasis should be used for those patients with high post-CRT CA19-9 levels.

Topic Category 醫藥衛生 > 外科
Reference
  1. 1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau, R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
    連結:
  2. 2. Glimelius B. Radiotherapy in rectal cancer. Br Med bull 2002;64:141-57.
    連結:
  3. 3. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644-50.
    連結:
  4. 4. McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane database of systematic reviews (Online) 2012;12:CD008368.
    連結:
  5. 5. Colorectal Cancer Collaborative Group contributors. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358:1291-304.
    連結:
  6. 6. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
    連結:
  7. 7. Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA, et al. The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum 2011;54:245-52.
    連結:
  8. 8. Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, et al. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2011;18:3271-7.
    連結:
  9. 9. Yang KL, Yang SH, Liang WY, Kuo YJ, Lin JK, Lin TC, et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013;8:43.
    連結:
  10. 10. Huang CS, Lin JK, Wang LW, Liang WY, Lin CC, Lan YT, et al. Assessment of the value of carcinoembryonic antigen reduction ratio as a prognosis factor in rectal cancer. Am J Surg. 2014; 1879-1883 (Electronic).
    連結:
  11. 11. Lin JK, Lin CC, Yang SH, Wang HS, Jiang JK, Lan YT, et al. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis 2011 Sep;26(9):1135-41
    連結:
  12. 12. Lin PC, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, et al. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer. Int J Colorectal Dis. 2012 Oct;27(10):1333-8.
    連結:
  13. 13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual 7th ed.: Springer; 2010.
    連結:
  14. 14. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23.
    連結:
  15. 16. Desch CE, Benson AB, 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical practice guideline. J Clin Oncol. 2005 Nov 20;23(33):8512-9.
    連結:
  16. 17. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer prognostic factors consensus conference. 2000.
    連結:
  17. 18. Bast RC J, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 Mar 15;19(6):1865-78
    連結:
  18. 19. Duffy MJ, van Dalen A, van Dalen A, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003 Apr;39(6):718-27.
    連結:
  19. 20. Locker, GY, Hamilton, S, Harris, J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006 Nov 20;24(33):5313-27.
    連結:
  20. 21. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM). Eur J Cancer 2007;43(9):1348-60.
    連結:
  21. 22. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999;10 Suppl 4:145-9.
    連結:
  22. 23. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic. Cancer Res. 1987 Oct 15;47(20):5501-3.
    連結:
  23. 25. Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol. 1997;66(4):238-43.
    連結:
  24. 27. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124(2):169-74.
    連結:
  25. 28. Nozoe T, Rikimaru T, Mori E, Okuyama T, Takahashi I. Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma. J Surg Oncol 2006;94(2):132-7.
    連結:
  26. 29. Berg EL, Magnani J, Warnock RA, Robinson MK, Butcher EC. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). Biochem Biophys Res Commun. 1992;184(2):1048-55.
    連結:
  27. 31. Colon cancer clinical practice guidelines in oncology. 2010. at (http://www.nccn.org/index.asp.)
    連結:
  28. 32. Kim NK, Baik SH, Seong JS, Kim H, Roh JK, Lee KY, et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Annal of Surg 2006;244:1024-30.
    連結:
  29. 33. Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, et al. Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys. 2010;77:1158-65.
    連結:
  30. 15. Glimelius, B. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, Br Med bull 2002;60:141-57.
  31. 24. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982 Dec 10;257(23):14365-9.
  32. 26. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, et al. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Hepatogastroenterology. 2003;50(51):696-9.
  33. 30. Nakayama T, Watanabe M, Teramoto T, Kitajima M. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer. Anticancer Res. 1997;17(2B):1379-82.